Pros | - | Larger AUM within category. | ||
Cons | - | - |
INDMoney rank | - | - | ||
Category | Equity,Index Funds | Equity,Index Funds | ||
Fund Age | 3 Years | 4 Years 10 Months | ||
Fund AUM | ₹94 Cr | ₹8943 Cr | ||
Min Investment | SIP ₹1000 Lumpsum ₹1000 | SIP ₹500 Lumpsum ₹1000 | ||
Expense Ratio | 0.37% | 0.45% | ||
Exit Load | 0% | 0% | ||
Benchmark Index | Nifty Pharma TR INR | Nifty200 Momentum 30 TR INR |
No of Holdings | 22 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (23.17%) Cipla Ltd (10.34%) Divi's Laboratories Ltd (9.87%) Dr Reddy's Laboratories Ltd (9.2%) Lupin Ltd (6.05%) | Bajaj Finance Ltd (5.44%) Bharti Airtel Ltd (5.21%) SBI Life Insurance Co Ltd (5.16%) InterGlobe Aviation Ltd (5.1%) Bajaj Finserv Ltd (5.07%) | ||
No of Sectors | 1 | 9 | ||
Top 3 Sectors | Health (100%) | Corporate (100%) Financial Services (50.42%) Industrial (14.31%) | ||
Equity % | 99.97% | 99.96% | ||
Debt % | - | - | ||
P/E | 32.49 | 40.06 | ||
P/B | 4.7 | 6.97 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.26% | -1.16% | ||
3-Month Return | 2.5% | 2.37% | ||
6-Month Return | 6.01% | -0.02% | ||
1-Year Return | 1.7% | -4.72% | ||
3-Year Return | 21.24% | 19.27% | ||
5-Year Return | - | - |
Sharpe | - | 0.63 | ||
Alpha | - | -0.16 | ||
Beta | - | 1 | ||
Standard Deviation | - | 17.82 | ||
Information Ratio | - | -1.04 |
Description | ICICI Prudential Nifty Pharma Index Fund is an equity fund.The fund could potentially beat inflation in the long-run. | UTI Nifty200 Momentum 30 Index Fund is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Nishit Patel,Ashwini Shinde | Ayush Jain,Sharwan Kumar Goyal |